Trials / Completed
CompletedNCT02879877
A First-In-Human Study With a Single Ascending Dose of UCB7858 in Healthy Volunteers
A Subject-blind, Investigator-blind, Randomized, Placebo-controlled, First-in-human Study Evaluating the Safety/Tolerability, Pharmacokinetics, Effect on Transglutaminase 2 Expression, and Occupancy of Single Ascending Intravenous and Subcutaneous Doses of UCB7858 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 78 (actual)
- Sponsor
- UCB Biopharma S.P.R.L. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study is designed to evaluate the safety and tolerability of UCB7858 when given as single ascending doses administered by intravenous or subcutaneous infusion in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | UCB7858 | |
| DRUG | Placebo |
Timeline
- Start date
- 2016-07-11
- Primary completion
- 2018-01-31
- Completion
- 2018-01-31
- First posted
- 2016-08-26
- Last updated
- 2019-08-21
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02879877. Inclusion in this directory is not an endorsement.